Cargando…

Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis

AIMS: To evaluate whether 2 years of treatment with bisphosphonates in combination with calcium/vitamin D supplements has an effect on lumbar spine and hip bone mineral density (BMD) in ankylosing spondylitis (AS) patients starting tumour necrosis factor‐α inhibitors or receiving conventional treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Arends, Suzanne, Wink, Freke, Veneberg, Joyce, Bos, Reinhard, van Roon, Eric, van der Veer, Eveline, Maas, Fiona, Spoorenberg, Anneke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328658/
https://www.ncbi.nlm.nih.gov/pubmed/32530102
http://dx.doi.org/10.1111/bcp.14431
_version_ 1784757772392333312
author Arends, Suzanne
Wink, Freke
Veneberg, Joyce
Bos, Reinhard
van Roon, Eric
van der Veer, Eveline
Maas, Fiona
Spoorenberg, Anneke
author_facet Arends, Suzanne
Wink, Freke
Veneberg, Joyce
Bos, Reinhard
van Roon, Eric
van der Veer, Eveline
Maas, Fiona
Spoorenberg, Anneke
author_sort Arends, Suzanne
collection PubMed
description AIMS: To evaluate whether 2 years of treatment with bisphosphonates in combination with calcium/vitamin D supplements has an effect on lumbar spine and hip bone mineral density (BMD) in ankylosing spondylitis (AS) patients starting tumour necrosis factor‐α inhibitors or receiving conventional treatment. Secondly, to explore the development of radiographic vertebral fractures. METHODS: Patients from the Groningen Leeuwarden AS cohort receiving bisphosphonates based on clinical indication and available 2‐year follow‐up BMD measurements were included. BMD of lumbar spine (L1–L4) and hip (total proximal femur) were measured using dual‐energy X‐ray absorptiometry. Spinal radiographs (Th4–L4) were scored for vertebral fractures according to the Genant method. RESULTS: In the 20 included patients (median 52 years, 14 males), lumbar spine and hip BMD Z‐scores increased significantly; median from −1.5 (interquartile range [IQR] −2.2 to 0.4) to 0.1 (IQR −1.5 to 1.0); P < .001 and median from −1.0 (IQR −1.6 to −0.7) to −0.8 (IQR −1.2 to 0.0); P = .006 over 2 years, respectively. In patients also treated with tumour necrosis factor‐α inhibitors (n = 11), lumbar spine and hip BMD increased significantly (median 2‐year change +8.6% [IQR 2.4 to 19.6; P = .009] and +3.6% [IQR 0.7–9.0; P = .007]). In patients on conventional treatment (n = 9), lumbar spine BMD increased significantly (median 2‐year change +3.6%; IQR 0.7 to 9.0; P = .011) and no improvement was seen in hip BMD (median −0.6%; IQR −3.1 to 5.1; P = .61). Overall, younger AS males with limited spinal radiographic damage showed most improvement in lumbar spine BMD. Four mild radiographic vertebral fractures developed in 3 patients and 1 fracture increased from mild to moderate over 2 years in postmenopausal women and middle‐aged men. CONCLUSION: This explorative observational cohort study in AS showed that 2 years of treatment with bisphosphonates in combination with calcium/vitamin D supplements significantly improves lumbar spine BMD. Mild radiographic vertebral fractures still occurred.
format Online
Article
Text
id pubmed-9328658
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93286582022-07-30 Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis Arends, Suzanne Wink, Freke Veneberg, Joyce Bos, Reinhard van Roon, Eric van der Veer, Eveline Maas, Fiona Spoorenberg, Anneke Br J Clin Pharmacol Original Articles AIMS: To evaluate whether 2 years of treatment with bisphosphonates in combination with calcium/vitamin D supplements has an effect on lumbar spine and hip bone mineral density (BMD) in ankylosing spondylitis (AS) patients starting tumour necrosis factor‐α inhibitors or receiving conventional treatment. Secondly, to explore the development of radiographic vertebral fractures. METHODS: Patients from the Groningen Leeuwarden AS cohort receiving bisphosphonates based on clinical indication and available 2‐year follow‐up BMD measurements were included. BMD of lumbar spine (L1–L4) and hip (total proximal femur) were measured using dual‐energy X‐ray absorptiometry. Spinal radiographs (Th4–L4) were scored for vertebral fractures according to the Genant method. RESULTS: In the 20 included patients (median 52 years, 14 males), lumbar spine and hip BMD Z‐scores increased significantly; median from −1.5 (interquartile range [IQR] −2.2 to 0.4) to 0.1 (IQR −1.5 to 1.0); P < .001 and median from −1.0 (IQR −1.6 to −0.7) to −0.8 (IQR −1.2 to 0.0); P = .006 over 2 years, respectively. In patients also treated with tumour necrosis factor‐α inhibitors (n = 11), lumbar spine and hip BMD increased significantly (median 2‐year change +8.6% [IQR 2.4 to 19.6; P = .009] and +3.6% [IQR 0.7–9.0; P = .007]). In patients on conventional treatment (n = 9), lumbar spine BMD increased significantly (median 2‐year change +3.6%; IQR 0.7 to 9.0; P = .011) and no improvement was seen in hip BMD (median −0.6%; IQR −3.1 to 5.1; P = .61). Overall, younger AS males with limited spinal radiographic damage showed most improvement in lumbar spine BMD. Four mild radiographic vertebral fractures developed in 3 patients and 1 fracture increased from mild to moderate over 2 years in postmenopausal women and middle‐aged men. CONCLUSION: This explorative observational cohort study in AS showed that 2 years of treatment with bisphosphonates in combination with calcium/vitamin D supplements significantly improves lumbar spine BMD. Mild radiographic vertebral fractures still occurred. John Wiley and Sons Inc. 2020-07-05 2021-02 /pmc/articles/PMC9328658/ /pubmed/32530102 http://dx.doi.org/10.1111/bcp.14431 Text en © 2020 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Arends, Suzanne
Wink, Freke
Veneberg, Joyce
Bos, Reinhard
van Roon, Eric
van der Veer, Eveline
Maas, Fiona
Spoorenberg, Anneke
Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis
title Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis
title_full Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis
title_fullStr Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis
title_full_unstemmed Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis
title_short Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis
title_sort bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328658/
https://www.ncbi.nlm.nih.gov/pubmed/32530102
http://dx.doi.org/10.1111/bcp.14431
work_keys_str_mv AT arendssuzanne bonemineraldensityimprovesduring2yearsoftreatmentwithbisphosphonatesinpatientswithankylosingspondylitis
AT winkfreke bonemineraldensityimprovesduring2yearsoftreatmentwithbisphosphonatesinpatientswithankylosingspondylitis
AT venebergjoyce bonemineraldensityimprovesduring2yearsoftreatmentwithbisphosphonatesinpatientswithankylosingspondylitis
AT bosreinhard bonemineraldensityimprovesduring2yearsoftreatmentwithbisphosphonatesinpatientswithankylosingspondylitis
AT vanrooneric bonemineraldensityimprovesduring2yearsoftreatmentwithbisphosphonatesinpatientswithankylosingspondylitis
AT vanderveereveline bonemineraldensityimprovesduring2yearsoftreatmentwithbisphosphonatesinpatientswithankylosingspondylitis
AT maasfiona bonemineraldensityimprovesduring2yearsoftreatmentwithbisphosphonatesinpatientswithankylosingspondylitis
AT spoorenberganneke bonemineraldensityimprovesduring2yearsoftreatmentwithbisphosphonatesinpatientswithankylosingspondylitis